BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 265] [Article Influence: 30.3] [Reference Citation Analysis]
Number Citing Articles
1 Horsager J, Bak-Fredslund K, Larsen LP, Villadsen GE, Bogsrud TV, Sørensen M. Optimal 2-[(18)F]fluoro-2-deoxy-D-galactose PET/CT protocol for detection of hepatocellular carcinoma. EJNMMI Res 2016;6:56. [PMID: 27341819 DOI: 10.1186/s13550-016-0206-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
2 Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 2014;5:78-94. [PMID: 24393789 DOI: 10.18632/oncotarget.1569] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
3 Gao R, Gabr A, Mouli S, Riaz A, Kulik L, Lewandowski RJ, Salem R. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study. J Vasc Interv Radiol 2020;31:401-408.e1. [PMID: 31983593 DOI: 10.1016/j.jvir.2019.08.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol 2015; 7(26): 2648-2663 [PMID: 26609342 DOI: 10.4254/wjh.v7.i26.2648] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 19.3] [Reference Citation Analysis]
5 Yu J, Ou Z, Lei Y, Chen L, Su Q, Zhang K. LncRNA MYCNOS facilitates proliferation and invasion in hepatocellular carcinoma by regulating miR-340. Hum Cell 2020;33:148-58. [PMID: 31776854 DOI: 10.1007/s13577-019-00303-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Lee S, Kang JH, Kim DY, Ahn SH, Park JY, Kim BK, Kim SU, Han KH. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. Hepatol Int. 2017;11:292-299. [PMID: 28324324 DOI: 10.1007/s12072-017-9792-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Wang Z, Qu K, Huang Z, Xu X, Zhang J, Zhang L, Liu S, Chang H, Lin T, Liu Y, Niu W, Liu C. Glutathione S-transferase O2 gene rs157077 polymorphism predicts response to transarterial chemoembolization in hepatocellular carcinoma. Tumor Biol 2015;36:6463-9. [DOI: 10.1007/s13277-015-3336-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
8 Sahlman P, Nissinen M, Pukkala E, Färkkilä M. Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study. Scandinavian Journal of Gastroenterology 2016;51:961-6. [DOI: 10.3109/00365521.2016.1157889] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
9 Thandassery RB, Goenka U, Goenka MK. Role of local ablative therapy for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S104-S111. [PMID: 25755601 DOI: 10.1016/j.jceh.2014.03.046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
10 Bak-Fredslund KP, Keiding S, Villadsen GE, Kramer S, Schlander S, Sørensen M. [18 F]-Fluoro-2-deoxy-D-galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma. Liver Int 2020;40:447-55. [PMID: 31705784 DOI: 10.1111/liv.14293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Swersky A, Kulik L, Kalyan A, Grace K, Caicedo JC, Lewandowski RJ, Salem R. Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Semin Intervent Radiol 2021;38:432-7. [PMID: 34629710 DOI: 10.1055/s-0041-1735528] [Reference Citation Analysis]
12 Yang X, Qu K, Tao J, Yin G, Han S, Liu Q, Sun H. Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2018;495:1807-14. [DOI: 10.1016/j.bbrc.2017.11.124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol. 2015;63:1238-1253. [PMID: 26150256 DOI: 10.1016/j.jhep.2015.06.026] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 12.2] [Reference Citation Analysis]
14 Laroia ST, Yadav K, Rastogi A, Kumar G, Kumar S, Sarin SK. Diagnostic efficacy of dynamic liver imaging using qualitative diagnostic algorithm versus LI-RADS v2018 lexicon for atypical versus classical HCC lesions: A decade of experience from a tertiary liver institute. Eur J Radiol Open 2020;7:100219. [PMID: 32083152 DOI: 10.1016/j.ejro.2020.100219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Xu LL, Zhang M, Yi PS, Zheng XB, Feng L, Lan C, Tang JW, Ren SS, Xu MQ. Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2017;37:974-980. [PMID: 29270762 DOI: 10.1007/s11596-017-1836-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lacaze L, Scotté M. Surgical treatment of intra hepatic recurrence of hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1755-1760 [PMID: 26167248 DOI: 10.4254/wjh.v7.i13.1755] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
17 Xin Y, Yang Y, Liu N, Chen Y, Wang Y, Zhang X, Li X, Zhou X. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol 2021;12:735-50. [PMID: 34012662 DOI: 10.21037/jgo-20-342] [Reference Citation Analysis]
18 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
19 Sangro B, Maini CL, Ettorre GM, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Sciuto R, Pizzi G, Lastoria S; European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY). Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging 2018;45:1721-30. [PMID: 29516130 DOI: 10.1007/s00259-018-3968-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
20 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
21 Li Z, Zhao X, Jiang P, Xiao S, Wu G, Chen K, Zhang X, Liu H, Han X, Wang S, Li X. HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: A retrospective case-control study. Medicine (Baltimore) 2016;95:e4224. [PMID: 27495026 DOI: 10.1097/MD.0000000000004224] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
22 Gómez FM, Patel PA, Stuart S, Roebuck DJ. Systematic review of ablation techniques for the treatment of malignant or aggressive benign lesions in children. Pediatr Radiol 2014;44:1281-9. [PMID: 24821394 DOI: 10.1007/s00247-014-3001-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
23 Sneiders D, Houwen T, Pengel LHM, Polak WG, Dor FJMF, Hartog H. Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. Transplantation. 2018;102:88-96. [PMID: 28885493 DOI: 10.1097/tp.0000000000001936] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Oh D, Shin SW, Park HC, Cho SK, Lim DH, Paik SW. Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy. Cancer Res Treat 2015;47:251-8. [PMID: 25578056 DOI: 10.4143/crt.2014.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
25 Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545-551. [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029] [Cited by in Crossref: 296] [Cited by in F6Publishing: 294] [Article Influence: 59.2] [Reference Citation Analysis]
26 Patterson AJ, Priest AN, Bowden DJ, Wallace TE, Patterson I, Graves MJ, Lomas DJ. Quantitative BOLD imaging at 3T: Temporal changes in hepatocellular carcinoma and fibrosis following oxygen challenge. J Magn Reson Imaging 2016;44:739-44. [PMID: 26892734 DOI: 10.1002/jmri.25189] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
27 Cao J, Dong Y, Fan P, Mao F, Chen K, Chen R, Huang B, Cheng Y, Wang WP. Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound. Clin Hemorheol Microcirc 2021. [PMID: 33682701 DOI: 10.3233/CH-201086] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ingle PV, Samsudin SZ, Chan PQ, Ng MK, Heng LX, Yap SC, Chai AS, Wong AS. Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag. 2016;12:445-455. [PMID: 27042086 DOI: 10.2147/tcrm.s92377] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
30 Baravelli CM, Sandberg S, Aarsand AK, Nilsen RM, Tollånes MC. Acute hepatic porphyria and cancer risk: a nationwide cohort study. J Intern Med 2017;282:229-40. [PMID: 28730628 DOI: 10.1111/joim.12646] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
31 Wang Y, Tang Z. A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. Onco Targets Ther 2018;11:8529-41. [PMID: 30555243 DOI: 10.2147/OTT.S188209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
32 Guarneri A, Franco P, Trino E, Campion D, Faletti R, Mirabella S, Gaia S, Ragona R, Diotallevi M, Saracco G, Salizzoni M, Ricardi U, Carucci P. Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3 cm. Med Oncol 2016;33. [DOI: 10.1007/s12032-016-0823-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
34 Le Gac G, Angenard G, Clément B, Laviolle B, Coulouarn C, Beloeil H. Local Anesthetics Inhibit the Growth of Human Hepatocellular Carcinoma Cells. Anesth Analg 2017;125:1600-9. [PMID: 28857796 DOI: 10.1213/ANE.0000000000002429] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
35 Kim DJ, Cho EJ, Yu KS, Jang IJ, Yoon JH, Park T, Cho JY. Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis. Cancers (Basel). 2019;11. [PMID: 31590436 DOI: 10.3390/cancers11101497] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
36 Cao J, Dong Y, Mao F, Wang W. Dynamic Three-Dimensional Contrast-Enhanced Ultrasound to Predict Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings. Biomed Res Int 2018;2018:6469703. [PMID: 30225261 DOI: 10.1155/2018/6469703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
37 Pivonello C, Negri M, De Martino MC, Napolitano M, de Angelis C, Provvisiero DP, Cuomo G, Auriemma RS, Simeoli C, Izzo F, Colao A, Hofland LJ, Pivonello R. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget 2016;7:9718-31. [PMID: 26756219 DOI: 10.18632/oncotarget.6836] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
38 Borba HHL, Rochau U, Wiens A, Sroczynski G, Siebert U, Ferreira VL, Minowa E, Pontarolo R. Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. Value Health Reg Issues 2019;20:95-102. [PMID: 31108456 DOI: 10.1016/j.vhri.2019.02.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Chan Y, Kabiling CS, Pillai VG, Aguilar G, Wang C, Chen C. Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model. World J Surg 2015;39:1510-8. [DOI: 10.1007/s00268-015-2975-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
40 Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control 2018;25:1073274817744621. [PMID: 29327594 DOI: 10.1177/1073274817744621] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 16.3] [Reference Citation Analysis]
41 Ryu SW, Bok GH, Jang JY, Jeong SW, Ham NS, Kim JH, Park EJ, Kim JN, Lee WC, Shim KY. Clinically useful diagnostic tool of contrast enhanced ultrasonography for focal liver masses: comparison to computed tomography and magnetic resonance imaging. Gut Liver. 2014;8:292-297. [PMID: 24827626 DOI: 10.5009/gnl.2014.8.3.292] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
42 Nadda N, Paul SB, Yadav DP, Kumar S, Sreenivas V, Saraya A, Gamanagatti S, Acharya SK, Shalimar, Nayak B. Prognostic and Therapeutic Potentials of OncomiRs Modulating mTOR Pathways in Virus-Associated Hepatocellular Carcinoma. Front Oncol 2020;10:604540. [PMID: 33614488 DOI: 10.3389/fonc.2020.604540] [Reference Citation Analysis]
43 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol 2015; 7(9): 1157-1167 [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 8.2] [Reference Citation Analysis]
44 Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, Steel JC, Jayachandran A. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Front Oncol. 2018;8:269. [PMID: 30057891 DOI: 10.3389/fonc.2018.00269] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 12.7] [Reference Citation Analysis]
45 Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer. 2015;15:465. [PMID: 26059447 DOI: 10.1186/s12885-015-1480-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 9.7] [Reference Citation Analysis]
46 Korhan P, Yılmaz Y, Bağırsakçı E, Güneş A, Topel H, Carr BI, Atabey N. Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:7568742. [PMID: 30425976 DOI: 10.1155/2018/7568742] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
47 Song W, Tian C, Wang K, Zhang RJ, Zou SB. The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with hepatocellular carcinoma: A meta-analysis. Sci Rep 2017;7:46601. [PMID: 28417972 DOI: 10.1038/srep46601] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
48 Rodriguez-Castro KI, Vitale A, Fadin M, Shalaby S, Zerbinati P, Sartori MT, Landi S, Pettinari I, Piscaglia F, Han G, Burra P, Simioni P, Senzolo M. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol. 2019;31:34-42. [PMID: 30188408 DOI: 10.1097/meg.0000000000001237] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 11.5] [Reference Citation Analysis]
49 Riveiro-barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG, Crespo J, Piqueras B, Pascasio JM, Comas C, Gutierrez ML, Aguirre A, Suárez E, García-samaniego J, Rivero M, Acero D, Fernandez-bermejo M, Moreno D, Sánchez-pobre P, de Cuenca B, Moreno-palomares JJ, Esteban R, Buti M. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. Dig Dis Sci 2017;62:784-93. [DOI: 10.1007/s10620-017-4448-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
50 Ding J, Jing X, Wang Y, Wang F, Wang Y, Du Z. Thermal ablation for hepatocellular carcinoma: a large-scale analysis of long-term outcome and prognostic factors. Clinical Radiology 2016;71:1270-6. [DOI: 10.1016/j.crad.2016.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
51 Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer 2018;18:1131. [PMID: 30453925 DOI: 10.1186/s12885-018-5081-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
52 Chen C, Huang T, Chang C, Li W, Lin T, Wang C. Central Hepatectomy Still Plays an Important Role in Treatment of Early-Stage Centrally Located Hepatocellular Carcinoma. World J Surg 2017;41:2830-7. [DOI: 10.1007/s00268-017-4096-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
53 Schütte K, Kipper M, Kahl S, Bornschein J, Götze T, Adolf D, Arend J, Seidensticker R, Lippert H, Ricke J. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion. 2013;87:147-159. [PMID: 23548687 DOI: 10.1159/000346743] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
54 Zhou L, Li J, Ai DL, Fu JL, Peng XM, Zhang LZ, Wang JY, Zhao Y, Yang B, Yu Q. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2014;44:711-717. [PMID: 24855686 DOI: 10.1093/jjco/hyu068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
55 Granata V, de Lutio di Castelguidone E, Fusco R, Catalano O, Piccirillo M, Palaia R, Izzo F, Gallipoli AD, Petrillo A. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area. Radiol Med. 2016;121:122-131. [PMID: 26345332 DOI: 10.1007/s11547-015-0582-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
56 Taylor-Robinson SD, Wong J, Crossey MM, Khan SA. Evidence is weak to support hepatocellular carcinoma screening in chronic liver disease. Evid Based Med 2015;20:59. [PMID: 25694341 DOI: 10.1136/ebmed-2014-110107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Eilard MS, Andersson M, Naredi P, Geronymakis C, Lindnér P, Cahlin C, Bennet W, Rizell M. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer 2019;19:568. [PMID: 31185950 DOI: 10.1186/s12885-019-5760-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
58 Roh YH, Kang BK, Jun DW, Lee CM, Kim M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci Rep 2021;11:13616. [PMID: 34193951 DOI: 10.1038/s41598-021-93038-6] [Reference Citation Analysis]
59 Chen VL, Le AK, Kim NG, Kim LH, Nguyen NH, Nguyen PP, Zhao C, Nguyen MH. Effects of Cirrhosis on Short-term and Long-term Survival of Patients With Hepatitis B-related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2016;14:887-895.e1. [PMID: 26820401 DOI: 10.1016/j.cgh.2015.12.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
60 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
61 Jindal A, Bhardwaj A, Kumar G, Sarin SK. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg. Am J Gastroenterol 2020;115:1624-33. [PMID: 32453061 DOI: 10.14309/ajg.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
62 Chen SL, Xiao H, Xie ZL, Shen JX, Chen ZB, Wang YQ, Li B, Peng ZW, Kuang M, Lai JM, Peng S. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC. Eur Radiol 2020;30:3473-85. [PMID: 32048035 DOI: 10.1007/s00330-019-06640-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
63 Li X, Jiang F, Ge Z, Chen B, Yu J, Xin M, Wang J, An L, Wei J, Wu L. Fructose-Bisphosphate Aldolase A Regulates Hypoxic Adaptation in Hepatocellular Carcinoma and Involved with Tumor Malignancy. Dig Dis Sci 2019;64:3215-27. [PMID: 31041640 DOI: 10.1007/s10620-019-05642-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
64 Llacer-Moscardo C, Riou O, Azria D, Bedos L, Ailleres N, Quenet F, Rouanet P, Ychou M, Fenoglietto P. Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results. Rep Pract Oncol Radiother 2017;22:141-9. [PMID: 28490985 DOI: 10.1016/j.rpor.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
65 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
66 Bogdanovic A, Bulajic P, Zuvela M, Bidzic N, Zivanovic M, Galun D. Impact of diseased liver parenchyma on perioperative outcome among patients with hepatocellular carcinoma undergoing hepatectomy: Experience from a developing country. Surg Oncol 2020;35:236-42. [PMID: 32932220 DOI: 10.1016/j.suronc.2020.09.009] [Reference Citation Analysis]
67 Lee SJ, Cho EH, Kim R, Kim YH, Lim CS, Kim SB. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg 2015;19:98-102. [PMID: 26379730 DOI: 10.14701/kjhbps.2015.19.3.98] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
68 Wang Y, Liu H, Liang D, Huang Y, Zeng Y, Xing X, Xia J, Lin M, Han X, Liao N, Liu X, Liu J. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics. J Proteomics 2017;150:230-41. [PMID: 27693406 DOI: 10.1016/j.jprot.2016.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
69 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
70 Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, Thornburg B, Marshall K, Salzig K, Williams M, del Castillo C, Ganger D, Hohlastos E, Baker T, Lewandowski RJ, Salem R. Same-day 90Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging 2016;43:2353-9. [DOI: 10.1007/s00259-016-3438-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
71 Abei M, Okumura T, Fukuda K, Hashimoto T, Araki M, Ishige K, Hyodo I, Kanemoto A, Numajiri H, Mizumoto M. A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiat Oncol. 2013;8:239. [PMID: 24131485 DOI: 10.1186/1748-717x-8-239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
72 Borgheresi A, Covey A, Yarmohammadi H, Boas FE, Ziv E, Getrajdman G, Erinjeri J, Jarnagin W, Harding JJ, D'Angelica M, Gonen M, Brown KT. Embolization with microspheres alone for hepatocellular carcinoma with portal vein tumor: analysis of outcome and liver function at disease progression. HPB (Oxford) 2020;22:588-94. [PMID: 31474455 DOI: 10.1016/j.hpb.2019.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Chen W, Chen X, Yang L, Wang G, Li J, Wang S, Chan Q, Xu D. Quantitative assessment of liver function with whole-liver T1rho mapping at 3.0T. Magn Reson Imaging 2018;46:75-80. [PMID: 29109053 DOI: 10.1016/j.mri.2017.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
74 Wischhusen JC, Chowdhury SM, Lee T, Wang H, Bachawal S, Devulapally R, Afjei R, Sukumar UK, Paulmurugan R. Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo. J Control Release 2020;321:272-84. [PMID: 32004588 DOI: 10.1016/j.jconrel.2020.01.051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
75 Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, Grassi R, Izzo F, Petrillo A. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. Oncotarget 2017;8:51224-37. [PMID: 28881643 DOI: 10.18632/oncotarget.17227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
76 Hendriks P, Noortman WA, Baetens TR, van Erkel AR, van Rijswijk CSP, van der Meer RW, Coenraad MJ, de Geus-Oei LF, Slump CH, Burgmans MC. Quantitative Volumetric Assessment of Ablative Margins in Hepatocellular Carcinoma: Predicting Local Tumor Progression Using Nonrigid Registration Software. J Oncol 2019;2019:4049287. [PMID: 31641353 DOI: 10.1155/2019/4049287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
77 Pinto-marques H, Silva S, Sobral M, Perdigoto R, Martins A, Barroso E. A Fair Chance for Everyone: Total Tumor Volume as a Selection Tool in Liver Transplantation for Hepatocellular Carcinoma. Dig Surg 2018;35:539-48. [DOI: 10.1159/000485848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Wu F, Li J, Du X, Zhang W, Lei P, Zhang Q. Long noncoding RNA AB019562 promotes cell proliferation and metastasis in human hepatocellular carcinoma. Mol Med Rep. 2017;16:69-74. [PMID: 28534955 DOI: 10.3892/mmr.2017.6612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
79 Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-radosavljevic M, Sieghart W. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. Journal of Hepatology 2014;61:1287-96. [DOI: 10.1016/j.jhep.2014.07.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 11.4] [Reference Citation Analysis]
80 Thompson SM, Wang J, Chandan VS, Glaser KJ, Roberts LR, Ehman RL, Venkatesh SK. MR elastography of hepatocellular carcinoma: Correlation of tumor stiffness with histopathology features-Preliminary findings. Magn Reson Imaging 2017;37:41-5. [PMID: 27845245 DOI: 10.1016/j.mri.2016.11.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
81 Dionisi F, Guarneri A, Dell'Acqua V, Leonardi M, Niespolo R, Macchia G, Comito T, Amichetti M, Franco P, Cilla S, Caravatta L, Alongi F, Mantello G. Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology. Radiol Med 2016;121:735-43. [PMID: 27255503 DOI: 10.1007/s11547-016-0650-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Chen L, Zhang L, Liang M, Bao J, Zhang J, Xia Y, Huang X, Wang J. Magnetic Resonance Imaging with Gadoxetic Acid Disodium for the Detection of Hepatocellular Carcinoma. Academic Radiology 2014;21:1603-13. [DOI: 10.1016/j.acra.2014.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
83 Cheng Z, Yang P, Lei Z, Zhang B, Si A, Yan Z, Xia Y, Li J, Wang K, Hartmann D, Hüser N, Lau WY, Shen F. Nomograms for prediction of long-term survival in elderly patients after partial hepatectomy for hepatocellular carcinoma. Surgery 2017;162:1231-40. [PMID: 29033225 DOI: 10.1016/j.surg.2017.07.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
84 Granata V, Fusco R, Filice S, Catalano O, Piccirillo M, Palaia R, Izzo F, Petrillo A. The current role and future prospectives of functional parameters by diffusion weighted imaging in the assessment of histologic grade of HCC. Infect Agent Cancer. 2018;13:23. [PMID: 29988667 DOI: 10.1186/s13027-018-0194-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
85 Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, Bang MH, Binh MT, Ky TD, Tung NL, Thinh NT, Sang VV, Thao LTP, Bock CT, Velavan TP, Meyer CG, Song LH, Toan NL. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:e0196081. [PMID: 29672637 DOI: 10.1371/journal.pone.0196081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
86 Hoffmann RT. [Liver metastases of colorectal cancer]. Radiologe 2017;57:90-6. [PMID: 28130578 DOI: 10.1007/s00117-017-0208-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
87 Dubbelboer IR, Sjögren E, Lennernäs H. Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment. AAPS J 2018;20:96. [PMID: 30167825 DOI: 10.1208/s12248-018-0251-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Schneider C, Nikitichev D, Xia W, Gurusamy K, Desjardins AE, Davidson BR. Multispectral tissue mapping: developing a concept for the optical evaluation of liver disease. J Med Imaging (Bellingham) 2020;7:066001. [PMID: 33376759 DOI: 10.1117/1.JMI.7.6.066001] [Reference Citation Analysis]
89 Cho YZ, Park SY, Choi EH, Baik SK, Kwon SO, Kim YJ, Cha SH, Kim MY. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study. Clin Mol Hepatol 2015;21:165-74. [PMID: 26157754 DOI: 10.3350/cmh.2015.21.2.165] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
90 Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol 2014; 6(9): 670-676 [PMID: 25276283 DOI: 10.4254/wjh.v6.i9.670] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
91 Dai W, Gao Q, Qiu J, Yuan J, Wu G, Shen G. Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma. Tumor Biol 2016;37:6307-13. [DOI: 10.1007/s13277-015-4501-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
92 Chen L, Zhang L, Bao J, Zhang J, Li C, Xia Y, Huang X, Wang J. Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut 2013;62:1520-1. [DOI: 10.1136/gutjnl-2013-305231] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
93 Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis. Liver Transpl 2017;23:1505-18. [PMID: 28886231 DOI: 10.1002/lt.24867] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
94 Wan L, Dong DH, Wu XN, Ding HF, Lu Q, Tian Y, Zhang XF, Li W. Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B? Med Sci Monit 2020;26:e926797. [PMID: 33060558 DOI: 10.12659/MSM.926797] [Reference Citation Analysis]
95 Pardo F, Pons JA, Castells L, Colmenero J, Gómez MÁ, Lladó L, Pérez B, Prieto M, Briceño J. VI consensus document by the Spanish Liver Transplantation Society. Gastroenterol Hepatol 2018;41:406-21. [PMID: 29866511 DOI: 10.1016/j.gastrohep.2018.05.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
96 Han Y, Shao N, Xi X, Hao X. Use of microwave ablation in the treatment of patients with multiple primary malignant tumors. Thorac Cancer 2017;8:365-71. [PMID: 28560833 DOI: 10.1111/1759-7714.12445] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
97 Granata V, Fusco R, Catalano O, Guarino B, Granata F, Tatangelo F, Avallone A, Piccirillo M, Palaia R, Izzo F, Petrillo A. Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for Hepatocellular carcinoma: correlation with histologic grade. Oncotarget 2016;7:79357-64. [PMID: 27764817 DOI: 10.18632/oncotarget.12689] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
98 Weledji EP, Nsagha DS, Enoworock G, Mouladje M. Familial hepatocellular carcinoma in an endemic area: two case reports. BMC Res Notes 2015;8:415. [PMID: 26342351 DOI: 10.1186/s13104-015-1366-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
99 Granata V, Fusco R, Avallone A, Catalano O, Filice F, Leongito M, Palaia R, Izzo F, Petrillo A. Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update. Infect Agent Cancer 2017;12:23. [PMID: 28465718 DOI: 10.1186/s13027-017-0132-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
100 Fu X, Mao L, Tang M, Yan X, Qiu Y, He J, Zhou T. Gross classification of solitary small hepatocellular carcinoma on preoperative computed tomography: Prognostic significance after radiofrequency ablation. Hepatol Res. 2016;46:298-305. [PMID: 26041379 DOI: 10.1111/hepr.12540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
101 Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZJ, Cai JQ, Ding YT, Li LQ, Zhang YB, Zheng QC, Xu GL, Li B, Zhou WP, Cai SW, Wang XY, Wen H, Peng XY, Zhang XW, Dai CL, Bie P, Xing BC, Fu ZR, Liu LX, Mu Y, Zhang L, Zhang QS, Jiang B, Qian HX, Wang YJ, Liu JF, Qin XH, Li Q, Yin P, Zhang ZW, Chen XP. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut 2018;67:2006-16. [PMID: 29802174 DOI: 10.1136/gutjnl-2018-315983] [Cited by in Crossref: 45] [Cited by in F6Publishing: 57] [Article Influence: 15.0] [Reference Citation Analysis]
102 Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med 2019;10:323-34. [PMID: 31572038 DOI: 10.2147/JBM.S186362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
103 Igaki H, Mizumoto M, Okumura T, Hasegawa K, Kokudo N, Sakurai H. A systematic review of publications on charged particle therapy for hepatocellular carcinoma. Int J Clin Oncol 2018;23:423-33. [PMID: 28871342 DOI: 10.1007/s10147-017-1190-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
104 Suzuki E, Chiba T, Ooka Y, Ogasawara S, Tawada A, Motoyama T, Kanogawa N, Saito T, Yoshikawa M, Yokosuka O. Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates? World J Gastroenterol 2015; 21(29): 8888-8893 [PMID: 26269678 DOI: 10.3748/wjg.v21.i29.8888] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
105 Zhong JH, Pan LH, Wang YY, Cucchetti A, Yang T, You XM, Ma L, Gong WF, Xiang BD, Peng NF, Wu FX, Li LQ. Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameter. Medicine (Baltimore) 2017;96:e6608. [PMID: 28403105 DOI: 10.1097/MD.0000000000006608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
106 Cornelis FH, Borgheresi A, Petre EN, Santos E, Solomon SB, Brown K. Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response. Cardiovasc Intervent Radiol 2018;41:104-11. [PMID: 28770316 DOI: 10.1007/s00270-017-1758-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
107 Hsu CY, Liu PH, Ho SY, Huang YH, Lee YH, Lee RC, Nagaria TS, Hou MC, Huo TI. Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. Liver Int 2018;38:1803-11. [PMID: 29608816 DOI: 10.1111/liv.13748] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
108 Fatourou EM, Tsochatzis EA. ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr 2014;3:415-8. [PMID: 25568865 DOI: 10.3978/j.issn.2304-3881.2014.07.01] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
109 Rho YS, Pagano I, Wong LL, Kwee SA, Acoba JD. Factors and Survival Implications associated with biopsy of hepatocellular carcinoma. HPB (Oxford) 2021;23:1054-60. [PMID: 33229278 DOI: 10.1016/j.hpb.2020.11.001] [Reference Citation Analysis]
110 Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z, Yao Z, Deng M. The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int 2021;21:92. [PMID: 33549093 DOI: 10.1186/s12935-021-01790-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Bae JS, Kim JH, Yu MH, Lee DH, Kim HC, Chung JW, Han JK. Diagnostic accuracy of gadoxetic acid-enhanced MR for small hypervascular hepatocellular carcinoma and the concordance rate of Liver Imaging Reporting and Data System (LI-RADS). PLoS One. 2017;12:e0178495. [PMID: 28558068 DOI: 10.1371/journal.pone.0178495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
112 He Y, Guo Y, Chen J, Hu X, Li X, Kong Y, Zhang X, Zhou X, Liu L, Hou J. Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study. J Cancer 2018;9:1385-93. [PMID: 29721048 DOI: 10.7150/jca.23725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Nouri YM, Kim JH, Yoon HK, Ko HK, Shin JH, Gwon DI. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol 2019;20:34-49. [PMID: 30627020 DOI: 10.3348/kjr.2018.0088] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
114 Tsochatzis E, Meyer T, O’beirne J, Burroughs AK. Transarterial chemoembolisation is not superior to embolisation alone: The recent European Association for the Study of the Liver (EASL)–European Organisation for Research and Treatment of Cancer (EORTC) guidelines. European Journal of Cancer 2013;49:1509-10. [DOI: 10.1016/j.ejca.2012.11.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
115 Chonprasertsuk S, Vilaichone RK. Epidemiology and treatment of hepatocellular carcinoma in Thailand. Jpn J Clin Oncol 2017;47:294-7. [PMID: 28042136 DOI: 10.1093/jjco/hyw197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
116 Kim JW, Lee CH, Kim SB, Park BN, Park YS, Lee J, Park CM. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules. J Magn Reson Imaging. 2017;45:1599-1608. [PMID: 27726242 DOI: 10.1002/jmri.25493] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
117 Wang J, Yuan X, Guo W, Xiang X, Wu Q, Fang M, Zhang W, Ding Z, Xie K, Fang J, Zhou H, Fu S. Sedation and Analgesia for Liver Cancer Percutaneous Radiofrequency Ablation: Fentanyl and Oxycodone Comparison. Int J Med Sci 2020;17:2194-9. [PMID: 32922181 DOI: 10.7150/ijms.47067] [Reference Citation Analysis]
118 Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: A Cancer Journal for Clinicians 2012;62:394-9. [DOI: 10.3322/caac.21161] [Cited by in Crossref: 498] [Cited by in F6Publishing: 529] [Article Influence: 55.3] [Reference Citation Analysis]
119 Ohuchi H, Hayama Y, Nakajima K, Kurosaki K, Shiraishi I, Nakai M. Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation. J Am Heart Assoc 2021;10:e016617. [PMID: 33538186 DOI: 10.1161/JAHA.120.016617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies. Cardiovasc Intervent Radiol 2016;39:801-14. [PMID: 26718962 DOI: 10.1007/s00270-015-1276-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
121 Yeh JH, Hung CH, Wang JH, Chen CH, Kee KM, Kuo CM, Yen YH, Cheng YF, Chen YY, Hsu HC, Lu SN. Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLoS One 2015;10:e0144893. [PMID: 26661388 DOI: 10.1371/journal.pone.0144893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Deng Y, Zhu J, Liu Z, Huang M, Chang DW, Gu J. Elevated systemic inflammatory responses, factors associated with physical and mental quality of life, and prognosis of hepatocellular carcinoma. Aging (Albany NY) 2020;12:4357-70. [PMID: 32145060 DOI: 10.18632/aging.102889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Hasab Allah M, Salama RM, Marie MS, Mandur AA, Omar H. Utility of point shear wave elastography in characterisation of focal liver lesions. Expert Rev Gastroenterol Hepatol. 2018;12:201-207. [PMID: 29219625 DOI: 10.1080/17474124.2018.1415144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
124 Pinto J, Azevedo R, Pereira E, Caldeira A. Ultrasonography in Gastroenterology: The Need for Training. GE Port J Gastroenterol 2018;25:308-16. [PMID: 30480048 DOI: 10.1159/000487156] [Reference Citation Analysis]
125 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
126 Papadatos D, Fowler KJ, Kielar AZ, Cui J, Sirlin CB. Cirrhosis and LI-RADS. Abdom Radiol (NY) 2018;43:26-40. [PMID: 29218367 DOI: 10.1007/s00261-017-1425-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
127 Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016; 8(21): 881-890 [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
128 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
129 Qu K, Wang Z, Fan H, Li J, Liu J, Li P, Liang Z, An H, Jiang Y, Lin Q, Dong X, Liu P, Liu C. MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma. Cell Death Dis. 2017;8:e2603. [PMID: 28182015 DOI: 10.1038/cddis.2016.352] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
130 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 15.7] [Reference Citation Analysis]
131 Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015;17:988-95. [PMID: 26607931 DOI: 10.1007/s12094-015-1451-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
132 Fung AKY, Cheng NMY, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Lai PBS, Ng KKC. Single-center experience on actual mid-term (≥5 years) and long-term (≥10 years) survival outcome in patients with hepatocellular carcinoma after curative hepatectomy: A bimodal distribution. Medicine (Baltimore) 2020;99:e23358. [PMID: 33235106 DOI: 10.1097/MD.0000000000023358] [Reference Citation Analysis]
133 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 108] [Article Influence: 13.6] [Reference Citation Analysis]
134 Kwo PY. Regimens for Cirrhotic Patients. Clin Liver Dis 2015;19:657-67, vi. [PMID: 26466654 DOI: 10.1016/j.cld.2015.06.006] [Reference Citation Analysis]
135 Wang Z, Kang F, Gao Y, Liu Y, Xu X, Ma X, Ma W, Yang W, Wang J. Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase. Mol Imaging Biol 2018;20:388-97. [DOI: 10.1007/s11307-017-1150-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
136 Galun D, Bogdanovic A, Zivanovic M, Zuvela M. Short- and Long-Term Outcomes After Hepatectomy in Elderly Patients with Hepatocellular Carcinoma: An Analysis of 229 Cases from a Developing Country. J Hepatocell Carcinoma 2021;8:155-65. [PMID: 33791251 DOI: 10.2147/JHC.S297296] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Karnsakul W, Schwarz KB. Hepatitis B and C. Pediatr Clin North Am. 2017;64:641-658. [PMID: 28502443 DOI: 10.1016/j.pcl.2017.01.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
138 Feng X, Song P, Bie P, Jiang P, Ma K, Li X, Wang S, Wang Z, Tang W, Zheng S. Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery. Med Sci Monit 2016;22:1663-72. [PMID: 27187589 DOI: 10.12659/msm.895483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
139 Delicque J, Hermida M, Piron L, Allimant C, Belgour A, Pageaux GP, Ben Bouallegue F, Assenat E, Mariano-Goulart D, Guiu B, Cassinotto C. Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization. Diagn Interv Imaging 2019;100:689-97. [PMID: 31281074 DOI: 10.1016/j.diii.2019.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
140 Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, Kudo M, Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K;  Liver Cancer Study Group of Japan. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109:1904-1907. [PMID: 24008659 DOI: 10.1038/bjc.2013.542] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
141 Li Y, Zhou F, Liu F, Wang M, Xing W. Experimental Study on Evaluation of Blood Supply Level and Embolization Ratio of Liver Cancer Based on I-Flow Software. Technol Cancer Res Treat 2020;19:1533033820970665. [PMID: 33174500 DOI: 10.1177/1533033820970665] [Reference Citation Analysis]
142 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 12.4] [Reference Citation Analysis]
143 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 2015;12:481-9. [PMID: 25985939 DOI: 10.1038/nrclinonc.2015.78] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
144 Bae JS, Lee JM, Yoon JH, Jang S, Chung JW, Lee KB, Yi NJ, Lee JH. How to Best Detect Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: Gadoxetic Acid-Enhanced MRI versus Contrast-Enhanced CT. Liver Cancer 2020;9:293-307. [PMID: 32647632 DOI: 10.1159/000505191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
145 Yao Q, Zhang H, Xiong B, Zheng C. Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study. Oncotarget 2017;8:79012-22. [PMID: 29108283 DOI: 10.18632/oncotarget.20745] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
146 Dhanasekaran R, Venkatesh SK, Torbenson MS, Roberts LR. Clinical implications of basic research in hepatocellular carcinoma. J Hepatol 2016;64:736-45. [PMID: 26450813 DOI: 10.1016/j.jhep.2015.09.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
147 Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, Chang JY, Whang-Peng J, Lin PW, Huang JD. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37:62-73. [PMID: 23134470 DOI: 10.1111/apt.12132] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
148 Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, Carrafiello G, Azoulay D, Petrillo A, Curley SA. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. Oncologist 2019;24:e990-e1005. [PMID: 31217342 DOI: 10.1634/theoncologist.2018-0337] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 37.5] [Reference Citation Analysis]
149 Gong SC, Cho MY, Lee SW, Kim SH, Kim MY, Baik SK. The meaning of gross tumor type in the aspects of cytokeratin 19 expression and resection margin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:206-12. [PMID: 26212571 DOI: 10.1111/jgh.13063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
150 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
151 Goldberg DS, Valderrama A, Kamalakar R, Sansgiry SS, Babajanyan S, Lewis JD. Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance. J Clin Gastroenterol 2016;50:258-65. [PMID: 26352107 DOI: 10.1097/MCG.0000000000000411] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
152 Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography 2019;38:200-14. [PMID: 31006227 DOI: 10.14366/usg.18060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
153 Chen YR, Li YT, Wang MQ, Zhu SL. Prognostic significance and function of MCM10 in human hepatocellular carcinoma. Future Oncol 2021. [PMID: 34350781 DOI: 10.2217/fon-2021-0225] [Reference Citation Analysis]
154 Song DS, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol. 2012;18:258-267. [PMID: 23091805 DOI: 10.3350/cmh.2012.18.3.258] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 6.3] [Reference Citation Analysis]
155 Ali R, Riaz A, Gabr A, Abouchaleh N, Mora R, Al Asadi A, Caicedo JC, Abecassis M, Katariya N, Maddur H, Kulik L, Lewandowski RJ, Salem R. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging 2017;44:2195-202. [DOI: 10.1007/s00259-017-3792-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
156 Qiu B, Wang J, Yu Y, Zhen C, Gu J, Liu W, Wen Y, Chen L, Gao Y, Xia Q, Kong X. DJ-1 promotes development of DEN-induced hepatocellular carcinoma and proliferation of liver cancer cells. Oncotarget 2017;8:8499-511. [PMID: 28036277 DOI: 10.18632/oncotarget.14293] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
157 Rammohan A, Jeswanth S, Sukumar R, Anand L, Kumar PS, Srinivasan UP, Ravi R, Ravichandran P. Percutaneous ultrasound-guided fine-needle aspiration of portal vein thrombi as a diagnostic and staging technique for hepatocellular carcinoma. Abdom Imaging. 2013;38:1057-1060. [PMID: 23579929 DOI: 10.1007/s00261-013-9997-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
158 Farinati F, Vanin V, Giacomin A, Pozzan C, Cillo U, Vitale A, Di Nolfo AM, Del Poggio P, Benvegnu’ L, Rapaccini G. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver Int. 2015;35:223-231. [PMID: 25074434 DOI: 10.1111/liv.12649] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
159 Li X, Liu S, Li H, Guo L, Zhang B, Lin Z, Zhang J, Ye Q. Proper hepatic pedicle clamping during hepatectomy is associated with improved postoperative long-term prognosis in patients with AJCC stage IIIB hepatocellular carcinoma. Oncotarget 2016;7:24623-32. [PMID: 27027437 DOI: 10.18632/oncotarget.8331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
160 McPhail MJW, Khorsandi SE, Abbott L, Al-Kadhimi G, Kane P, Karani J, O'Grady J, Heaton N, Bomford A, Suddle A. Modern Outcomes Following Treatment of Hepatocellular Carcinoma in Hereditary Hemochromatosis: A Matched Cohort Study. Am J Clin Oncol 2019;42:918-23. [PMID: 31436748 DOI: 10.1097/COC.0000000000000583] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3069-3077 [PMID: 24695579 DOI: 10.3748/wjg.v20.i12.3069] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
162 Yang XP, Zhou LX, Yang QJ, Liu L, Cai Y, Ma SL. Diagnostic and prognostic roles of serum vitronectin in hepatitis B-related hepatocellular carcinoma. Cancer Biomark 2016;17:271-9. [PMID: 27802203 DOI: 10.3233/CBM-160639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Seuss CR, Kim MJ, Triolo MJ, Hajdu CH, Rosenkrantz AB. Comparison of MRI Pulse Sequences for Prediction of Size of Hepatocellular Carcinoma at Explant Evaluation. American Journal of Roentgenology 2014;203:300-5. [DOI: 10.2214/ajr.13.11688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
164 Timaran Montenegro DE, Torres Ramirez CA, Mateo C YS, Govea Palma J, Quiñones JC, Orozco Vazquez JS. CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuitable for Surgical Therapy Undergoing Transarterial Chemoembolization. Acad Radiol 2020;27:807-14. [PMID: 31575476 DOI: 10.1016/j.acra.2019.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
165 Kubota K, Hidaka H, Nakazawa T, Okuwaki Y, Yamane K, Inoue T, Uojima H, Takada J, Tanaka Y, Shibuya A, Fujii K, Woodhams R, Matsunaga K, Kokubu S, Koizumi W. Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma: TACE with miriplatin in Japanese HCC patients. Hepatol Res 2018;48:E98-E106. [DOI: 10.1111/hepr.12933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
166 Han DH, Choi SH, Park EJ, Kang DR, Choi GH, Choi JS. Surgical outcomes after laparoscopic or robotic liver resection in hepatocellular carcinoma: a propensity-score matched analysis with conventional open liver resection. Int J Med Robot. 2016;12:735-742. [PMID: 26537176 DOI: 10.1002/rcs.1714] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
167 Cvetkovic S, Koncar I, Galun D, Ribac J, Markovic M, Ilic N, Dragas M, Davidovic L. Treatment of a Patient with Abdominal Aortic Aneurysm and Hepatocellular Carcinoma. Ann Vasc Surg 2017;40:295.e1-4. [PMID: 27890842 DOI: 10.1016/j.avsg.2016.07.075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Weledji EP. Familial hepatocellular carcinoma: 'A model for studying preventive and therapeutic measures'. Ann Med Surg (Lond) 2018;35:129-32. [PMID: 30305894 DOI: 10.1016/j.amsu.2018.09.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 He J, Liu Y. Serum TGF-β1: A Potential Biomarker for Early Detection of Hepatocellular Carcinoma. EBioMedicine 2016;12:4-5. [PMID: 27665049 DOI: 10.1016/j.ebiom.2016.09.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
170 Tsochatzis A, Mazioti A, Iliadis G, Velonakis G, Efthymiou E, Kelekis A, Kelekis N, Filippiadis D. Percutaneous Microwave Ablation of Liver Lesions: Differences on the Sphericity Index of the Ablation Zone between Cirrhotic and Healthy Liver Parenchyma. Diagnostics (Basel) 2021;11:655. [PMID: 33916400 DOI: 10.3390/diagnostics11040655] [Reference Citation Analysis]
171 Chen ZH, Hong YF, Chen X, Chen J, Lin Q, Lin J, Li X, Wen JY, Ruan DY, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu DH, Wu XY, Xu R. Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization therapy. Oncol Lett 2018;15:855-62. [PMID: 29403561 DOI: 10.3892/ol.2017.7419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
172 Zhong JH. The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma. Tumour Biol. 2015;36:8271-8272. [PMID: 26499777 DOI: 10.1007/s13277-015-4279-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
173 Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget 2017;8:33911-21. [PMID: 28430610 DOI: 10.18632/oncotarget.15411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
174 Lisotti A, Azzaroli F, Cucchetti A, Buonfiglioli F, Cecinato P, Calvanese C, Simoni P, Arena R, Montagnani M, Golfieri R, Colecchia A, Festi D, Mazzella G. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. Liver Int. 2016;36:1313-1321. [PMID: 26786880 DOI: 10.1111/liv.13070] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
175 Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford) 2013;15:985-90. [PMID: 23607636 DOI: 10.1111/hpb.12080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
176 Liu Z, Yu Y, Huang Z, Kong Y, Hu X, Xiao W, Quan J, Fan X. CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression. Cell Death Dis 2019;10:900. [PMID: 31776329 DOI: 10.1038/s41419-019-2089-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 27.0] [Reference Citation Analysis]
177 Galun D, Bogdanovic A, Djokic Kovac J, Bulajic P, Loncar Z, Zuvela M. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative-intent surgery for hepatocellular carcinoma: experience from a developing country. Cancer Manag Res. 2018;10:977-988. [PMID: 29765248 DOI: 10.2147/cmar.s161398] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
178 Qiao Y, Chen J, Li X, Wei H, Xiao F, Chang L, Zhang R, Hao X, Wei H. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem. 2014;47:216-222. [PMID: 25168922 DOI: 10.1016/j.clinbiochem.2014.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
179 Lilienberg E, Ebeling Barbier C, Nyman R, Hedeland M, Bondesson U, Axén N, Lennernäs H. Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. Mol Pharm 2014;11:131-44. [PMID: 24171458 DOI: 10.1021/mp4002574] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
180 Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115:211-216. [PMID: 26028227 DOI: 10.1016/j.radonc.2015.04.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 13.7] [Reference Citation Analysis]
181 Yeh JH, Hung CH, Wang JH, Kuo YH, Tai WC, Lu SN. Hepatocellular carcinoma detected by regular surveillance: Does timely confirmation of diagnosis matter? Dig Liver Dis 2016;48:661-6. [PMID: 26992848 DOI: 10.1016/j.dld.2016.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
182 Hashad DI, Elyamany AS, Salem PE. Mitochondrial DNA Copy Number in Egyptian Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma. Genet Test Mol Biomarkers 2015;19:604-9. [PMID: 26447820 DOI: 10.1089/gtmb.2015.0132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
183 Çelebi F, Yaghouti K, Cindil E, Dogusoy GB, Tokat Y, Balcı C. The Role of 18F-FDG PET/MRI in the Assessment of Primary Intrahepatic Neoplasms. Acad Radiol 2021;28:189-98. [PMID: 32111468 DOI: 10.1016/j.acra.2020.01.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49:3412-3419. [PMID: 23809766 DOI: 10.1016/j.ejca.2013.05.028] [Cited by in Crossref: 146] [Cited by in F6Publishing: 135] [Article Influence: 18.3] [Reference Citation Analysis]
185 Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
186 Ma L, Wang X, Jia T, Wei W, Chua MS, So S. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget. 2015;6:25390-25401. [PMID: 26246473 DOI: 10.18632/oncotarget.4455] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 10.2] [Reference Citation Analysis]
187 Cheng H, Xue J, Yang S, Chen Y, Wang Y, Zhu Y, Wang X, Kuang D, Ruan Q, Duan Y. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. Oncotarget. 2017;8:47984-47997. [PMID: 28624790 DOI: 10.18632/oncotarget.18207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
188 Li XH, Liang Q, Chen TW, Wang J, Zhang XM. Diagnostic value of imaging examinations in patients with primary hepatocellular carcinoma. World J Clin Cases 2018; 6(9): 242-248 [PMID: 30211204 DOI: 10.12998/wjcc.v6.i9.242] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
189 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 37] [Article Influence: 22.0] [Reference Citation Analysis]
190 Kim JH, Joo I, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol 2019;20:1019-41. [PMID: 31270973 DOI: 10.3348/kjr.2018.0636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
191 Antonelli G, Gigante E, Iavarone M, Begini P, Sangiovanni A, Iannicelli E, Biondetti P, Pellicelli AM, Miglioresi L, Marchetti P, Lampertico P, Marignani M. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United European Gastroenterol J 2018;6:1039-48. [PMID: 30228892 DOI: 10.1177/2050640618781188] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
192 Huang Z, Zhang P, Wang H, Yan L, Wang W. Comparing outcomes of two vascular inflow occlusion techniques and treatment without vascular occlusion during major hepatectomy in patients with Hepatitis B-related hepatocellular carcinoma. PLoS One 2014;9:e107303. [PMID: 25203056 DOI: 10.1371/journal.pone.0107303] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
193 Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther 2017;45:1514-23. [DOI: 10.1111/apt.14066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
194 Mullick Chowdhury S, Wang TY, Bachawal S, Devulapally R, Choe JW, Abou Elkacem L, Yakub BK, Wang DS, Tian L, Paulmurugan R, Willmann JK. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J Control Release 2016;238:272-80. [PMID: 27503707 DOI: 10.1016/j.jconrel.2016.08.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
195 Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Mitchell DG, Cerny M, Elsayes KM, Santillan C, Kamaya A, Kono Y, Sirlin CB, Tang A. LI-RADS 2017: An update. J Magn Reson Imaging 2018;47:1459-74. [PMID: 29626376 DOI: 10.1002/jmri.26027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
196 Pardo F, Pons JA, Castells L, Colmenero J, Gómez MÁ, Lladó L, Pérez B, Prieto M, Briceño J. VI consensus document by the Spanish Liver Transplantation Society. Cir Esp (Engl Ed) 2018;96:326-41. [PMID: 29776591 DOI: 10.1016/j.ciresp.2017.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
197 Brahmania M, Ahmed O, Kelley M, Wong D, Kowgier M, Khalili K, Beecroft R, Renner EL, Shah H, Feld J, Janssen HLA, Sherman M. Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma. Ann Hepatol 2017;16:765-71. [PMID: 28809734 DOI: 10.5604/01.3001.0010.2776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
198 Willatt J, Hannawa KK, Ruma JA, Frankel TL, Owen D, Barman PM. Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective. World J Hepatol 2015; 7(2): 235-244 [PMID: 25729478 DOI: 10.4254/wjh.v7.i2.235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
199 Jacobs C, Graham ID, Makarski J, Chassé M, Fergusson D, Hutton B, Clemons M. Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. PLoS One 2014;9:e110469. [PMID: 25329669 DOI: 10.1371/journal.pone.0110469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
200 Abouchaleh N, Gabr A, Ali R, Al Asadi A, Mora RA, Kallini JR, Mouli S, Riaz A, Lewandowski RJ, Salem R. 90 Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort. J Nucl Med 2018;59:1042-8. [DOI: 10.2967/jnumed.117.199752] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
201 Brunsing RL, Chen DH, Schlein A, Wolfson T, Gamst A, Mamidipalli A, Violi NV, Marks RM, Taouli B, Loomba R, Kono Y, Sirlin CB. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience. Radiol Imaging Cancer 2019;1:e190010. [PMID: 33778680 DOI: 10.1148/rycan.2019190010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
202 Ikeda K, Kawamura Y, Kobayashi M, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma: Warmed miriplatin for multiple HCC. Hepatol Res 2017;47:632-40. [DOI: 10.1111/hepr.12782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
203 Liu Y, Xue D, Zhang X, Gao F, Sun L, Yang X, Li Y, Zhang Q, Zhu B, Niu S, Huang Y, Hu Y, Wang X. Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment. Biomed Res Int 2020;2020:1473718. [PMID: 32149077 DOI: 10.1155/2020/1473718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Charriere B, Muscari F, Maulat C, Bournet B, Bonnet D, Bureau C, Otal P, Peron J, Suc B. Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings: Treatment of Hepatocellular Carcinoma. J Surg Oncol 2017;115:330-6. [DOI: 10.1002/jso.24500] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
205 Choi YR, Chung JW, Yu MH, Lee M, Kim JH. Diagnostic accuracy of contrast-enhanced dynamic CT for small hypervascular hepatocellular carcinoma and assessment of dynamic enhancement patterns: Results of two-year follow-up using cone-beam CT hepatic arteriography. PLoS One. 2018;13:e0203940. [PMID: 30231076 DOI: 10.1371/journal.pone.0203940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
206 Guo J, Wang W, Zhang Y, Xu L, Kong J. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis. J Gastrointest Oncol 2021;12:1838-50. [PMID: 34532132 DOI: 10.21037/jgo-21-370] [Reference Citation Analysis]
207 Martins-Filho SN, Alves VAF, Wakamatsu A, Maeda M, Craig AJ, Assato AK, Villacorta-Martin C, D'Avola D, Labgaa I, Carrilho FJ, Thung SN, Villanueva A. A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. Histopathology. 2019;74:718-730. [PMID: 30636011 DOI: 10.1111/his.13809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
208 Kang X, Li F, Gao H, Wang S. Imaging performance and preoperative differential diagnosis of multiple myopericytoma in the liver: A case report. Mol Clin Oncol 2020;13:66. [PMID: 33014365 DOI: 10.3892/mco.2020.2136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, Wang WT, Xu MQ, Yang JY. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol 2013; 19(11): 1811-1819 [PMID: 23555170 DOI: 10.3748/wjg.v19.i11.1811] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 67] [Article Influence: 8.4] [Reference Citation Analysis]
210 Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
211 Cheng YT, Jeng WJ, Lin CC, Chen WT, Sheen IS, Lin CY, Lin SM. Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma. Biomed J 2016;39:400-6. [PMID: 28043419 DOI: 10.1016/j.bj.2016.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
212 Veloso Gomes F, Oliveira JA, Correia MT, Costa NV, Abrantes J, Torres D, Pereira P, Ferreira AI, Luz JH, Spaepen E, Bilhim T, Coimbra É. Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients. Journal of Vascular and Interventional Radiology 2018;29:841-9. [DOI: 10.1016/j.jvir.2018.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
213 Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology 2019;8:1615817. [PMID: 31413923 DOI: 10.1080/2162402X.2019.1615817] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 15.5] [Reference Citation Analysis]
214 Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, Camacho J. Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma. Biologics 2016;10:139-48. [PMID: 27703327 DOI: 10.2147/BTT.S87402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
215 Mo HY, Liao YY, You XM, Cucchetti A, Yuan BH, Li RH, Zhong JH, Li LQ. Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. PLoS One 2017;12:e0174222. [PMID: 28339493 DOI: 10.1371/journal.pone.0174222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
216 Liu Z, Zhang Z, Mei H, Mao J, Zhou X. Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. Hepatol Int 2020;14:544-55. [PMID: 32504407 DOI: 10.1007/s12072-020-10056-8] [Reference Citation Analysis]
217 Tian Y, Lyu H, He Y, Kanduri HK. Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC. J Gastrointest Cancer 2019;50:400-7. [PMID: 29512001 DOI: 10.1007/s12029-018-0085-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015; 7(20): 2274-2291 [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
219 Yang JF, Lo CH, Lee MS, Lin CS, Dai YH, Shen PC, Chao HL, Huang WY. Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis. Radiat Oncol 2019;14:180. [PMID: 31640728 DOI: 10.1186/s13014-019-1382-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
220 Dietrich CF, Potthoff A, Helmberger T, Ignee A, Willmann JK; on behalf of the CEUS LI-RADS Working Group. Standardisierte Befundung und Dokumentation der Kontrastmittelsonografie der Leber (CEUS LI-RADS). Z Gastroenterol 2018;56:499-506. [DOI: 10.1055/s-0043-124874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
221 Goldberg DS, Valderrama A, Kamalakar R, Sansgiry SS, Babajanyan S, Lewis JD. Hepatocellular carcinoma surveillance rates in commercially insured patients with noncirrhotic chronic hepatitis B. J Viral Hepat 2015;22:727-36. [PMID: 25581816 DOI: 10.1111/jvh.12381] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
222 Lauber DT, Tihanyi DK, Czigány Z, Kovács T, Budai A, Drozgyik D, Fülöp A, Szijártó A. Liver regeneration after different degrees of portal vein ligation. J Surg Res 2016;203:451-8. [PMID: 27363655 DOI: 10.1016/j.jss.2016.03.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
223 Ma Y, Bian J, Zhang F. Inhibition of perillyl alcohol on cell invasion and migration depends on the Notch signaling pathway in hepatoma cells. Mol Cell Biochem 2016;411:307-15. [PMID: 26475687 DOI: 10.1007/s11010-015-2593-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
224 Garwood ER, Fidelman N, Hoch SE, Kerlan RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction: High-Risk Transarterial Chemoembolization Outcomes. Liver Transpl 2013;19:164-73. [DOI: 10.1002/lt.23552] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
225 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
226 Pinato DJ, Pai M, Reccia I, Patel M, Giakoustidis A, Karamanakos G, Rushd A, Jamshaid S, Oldani A, Grossi G, Pirisi M, Tait P, Sharma R. Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma. BMC Cancer 2018;18:211. [PMID: 29463228 DOI: 10.1186/s12885-018-4120-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
227 Sinn M, Nicolaou A, Ricke J, Podrabsky P, Seehofer D, Gebauer B, Pech M, Neuhaus P, Dörken B, Riess H, Hildebrandt B. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161). BMC Gastroenterol 2013;13:125. [PMID: 23927554 DOI: 10.1186/1471-230X-13-125] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
228 Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018;24:219-24. [PMID: 29792289 DOI: 10.5152/dir.2018.17528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
229 Jiang E, Shangguan AJ, Chen S, Tang L, Zhao S, Yu Z. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. Cancer Lett 2016;379:262-7. [PMID: 26272181 DOI: 10.1016/j.canlet.2015.07.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
230 Nagarajan V, Chandiramouli R. A study on quercetin and 5-fluorouracil drug interaction on graphyne nanosheets and solvent effects — A first-principles study. Journal of Molecular Liquids 2019;275:713-22. [DOI: 10.1016/j.molliq.2018.11.083] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
231 Tang Z, Peng H, Chen J, Liu Y, Yan S, Yu G, Chen Q, Tang H, Liu S. Rap1b enhances the invasion and migration of hepatocellular carcinoma cells by up-regulating Twist 1. Exp Cell Res 2018;367:56-64. [PMID: 29559227 DOI: 10.1016/j.yexcr.2018.03.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
232 Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K, Krawczyk M. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 2014;38:2698-707. [PMID: 24858191 DOI: 10.1007/s00268-014-2647-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
233 Grammatikos G, Schoell N, Ferreirós N, Bon D, Herrmann E, Farnik H, Köberle V, Piiper A, Zeuzem S, Kronenberger B, Waidmann O, Pfeilschifter J. Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma. Oncotarget 2016;7:18095-105. [PMID: 26933996 DOI: 10.18632/oncotarget.7741] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
234 Chen J, Zhou C, Long Y, Yin X. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Tumour Biol 2015;36:183-91. [PMID: 25217986 DOI: 10.1007/s13277-014-2608-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
235 Lu LH, Wei-Wei, Kan A, Jie-Mei, Ling YH, Li SH, Guo RP. Novel Value of Preoperative Gamma-Glutamyltransferase Levels in the Prognosis of AFP-Negative Hepatocellular Carcinoma. Dis Markers 2020;2020:4269460. [PMID: 32695241 DOI: 10.1155/2020/4269460] [Reference Citation Analysis]
236 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
237 Ho VL, Pham NH, Nguyen TX, Tran AP, Dang NT, Pham NH. Hepatectomy with Takasaki's Technique Using SonaStar Ultrasonic Aspiration System: An Experience from 58 Cases. Clin Exp Gastroenterol 2021;14:297-302. [PMID: 34188512 DOI: 10.2147/CEG.S319434] [Reference Citation Analysis]
238 Baravelli CM, Sandberg S, Aarsand AK, Tollånes MC. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study. Orphanet J Rare Dis 2019;14:77. [PMID: 30944007 DOI: 10.1186/s13023-019-1051-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
239 Danielsson Borssén Å, Almer S, Prytz H, Wallerstedt S, Friis-Liby IL, Bergquist A, Nyhlin N, Hultcrantz R, Sangfelt P, Weiland O, Lindgren S, Verbaan H, Werner M. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients. Scand J Gastroenterol 2015;50:217-23. [PMID: 25483724 DOI: 10.3109/00365521.2014.983154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
240 Li F, Li Q, Liu Y, Han J, Zheng W, Huang Y, Zheng X, Cao L, Zhou J. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. Eur Radiol 2020;30:461-70. [DOI: 10.1007/s00330-019-06317-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
241 Dhayat SA, Hüsing A, Senninger N, Schmidt HH, Haier J, Wolters H, Kabar I. Circulating microRNA-200 Family as Diagnostic Marker in Hepatocellular Carcinoma. PLoS One 2015;10:e0140066. [PMID: 26447841 DOI: 10.1371/journal.pone.0140066] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
242 Dongiovanni P, Meroni M, Petta S, Longo M, Alisi A, Soardo G, Valenti L, Miele L, Grimaudo S, Pennisi G, Antonio G, Consonni D, Fargion S, Fracanzani AL. Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158765. [PMID: 32663609 DOI: 10.1016/j.bbalip.2020.158765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
243 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 76] [Article Influence: 24.3] [Reference Citation Analysis]
244 Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. AJR Am J Roentgenol 2017;209:722-32. [PMID: 28705059 DOI: 10.2214/AJR.17.18219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
245 Ahn DG, Kim HJ, Kang H, Lee HW, Bae SH, Lee JH, Paik YH, Lee JS. Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea. Korean J Intern Med 2016;31:46-53. [PMID: 26767857 DOI: 10.3904/kjim.2016.31.1.46] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
246 Lu LH, Wei W, Li SH, Zhang YF, Guo RP. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE. Aging (Albany NY) 2021;13:5358-68. [PMID: 33589570 DOI: 10.18632/aging.202468] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
247 Ruan DY, Lin ZX, Wang TT, Zhao H, Wu DH, Chen J, Dong M, Lin Q, Wu XY, Li Y. Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1. Oncotarget 2016;7:61378-89. [PMID: 27542216 DOI: 10.18632/oncotarget.11358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
248 Fidelman N, Kerlan RK Jr. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease. AJR Am J Roentgenol 2015;205:742-52. [PMID: 26397322 DOI: 10.2214/AJR.15.14802] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
249 de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, Matsui O, Soulen MC. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. Cardiovasc Intervent Radiol. 2016;39:334-343. [PMID: 26390875 DOI: 10.1007/s00270-015-1208-y] [Cited by in Crossref: 110] [Cited by in F6Publishing: 92] [Article Influence: 18.3] [Reference Citation Analysis]
250 Frühling P, Nilsson A, Duraj F, Haglund U, Norén A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results. Eur J Surg Oncol 2017;43:751-7. [PMID: 28109674 DOI: 10.1016/j.ejso.2016.12.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
251 Dionisi F, Ben-josef E. The Use of Proton Therapy in the Treatment of Gastrointestinal Cancers: Liver. The Cancer Journal 2014;20:371-7. [DOI: 10.1097/ppo.0000000000000082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
252 Wu Y, Zhou D, Xu X, Zhao X, Huang P, Zhou X, Song W, Guo H, Wang W, Zheng S. Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma. World J Surg Oncol 2016;14:179. [PMID: 27389277 DOI: 10.1186/s12957-016-0922-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
253 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718. e1. [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064] [Cited by in Crossref: 242] [Cited by in F6Publishing: 234] [Article Influence: 80.7] [Reference Citation Analysis]
254 Kong Q, Fan Q, Ma X, Li J, Ma R. CircRNA circUGGT2 Contributes to Hepatocellular Carcinoma Development via Regulation of the miR-526b-5p/RAB1A Axis. Cancer Manag Res 2020;12:10229-41. [PMID: 33116877 DOI: 10.2147/CMAR.S263985] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
255 Piciocchi M, Cardin R, Vitale A, Vanin V, Giacomin A, Pozzan C, Maddalo G, Cillo U, Guido M, Farinati F. Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. Hepatol Int. 2013;7:1050-1057. [PMID: 26202034 DOI: 10.1007/s12072-013-9481-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
256 Zhou C, Huang Y, Shu C, Zhou J, Hu X, Wang J, Wang Y, Zhang Z, Chen L, Chen X, Zhang Z. Splenectomy before hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A retrospective study. Medicine (Baltimore) 2021;100:e24326. [PMID: 33530224 DOI: 10.1097/MD.0000000000024326] [Reference Citation Analysis]
257 Zhang L, Wu L, Chen Q, Zhang B, Liu J, Liu S, Mo X, Li M, Chen Z, Chen L, You J, Jin Z, Chen X, Zhou Z, Zhang S. Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. EClinicalMedicine 2021;31:100673. [PMID: 33554079 DOI: 10.1016/j.eclinm.2020.100673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
258 Sahlman P, Nissinen M, Pukkala E, Färkkilä M. Cancer incidence among alcoholic liver disease patients in Finland: A retrospective registry study during years 1996-2013: A retrospective registry study. Int J Cancer 2016;138:2616-21. [DOI: 10.1002/ijc.29995] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
259 Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5232. [PMID: 32718047 DOI: 10.3390/ijms21155232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Ni J, Fang Z, An C, Sun H, Huang Z, Zhang T, Jiang X, Chen Y, Xu L, Huang J. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. International Journal of Hyperthermia 2019;36:840-52. [DOI: 10.1080/02656736.2019.1646927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
261 Chen J, Wu G, Li Y. Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis. Dis Markers. 2018;2018:8906023. [PMID: 30402170 DOI: 10.1155/2018/8906023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
262 Shim JH, Han S, Shin YM, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC. Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma. J Magn Reson Imaging 2015;41:1115-23. [PMID: 24841479 DOI: 10.1002/jmri.24660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
263 Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zhong JH, Li LQ. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017;5:169-176. [PMID: 28660155 DOI: 10.14218/jcth.2016.00071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
264 Lin L, Xiang X, Su S, Liu S, Xiong Y, Ma H, Yuan G, Nie D, Tang G. Biological Evaluation of [18F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma. Front Chem 2021;9:630452. [PMID: 33937189 DOI: 10.3389/fchem.2021.630452] [Reference Citation Analysis]
265 Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int 2017;37:259-70. [PMID: 27427866 DOI: 10.1111/liv.13204] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]